{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    6,
    7,
    8,
    9,
    10,
    11,
    12,
    13,
    14,
    15,
    16,
    17,
    18,
    19,
    20,
    21,
    22,
    23,
    24,
    25,
    26,
    27,
    28,
    29,
    30,
    33,
    34,
    35,
    36,
    37,
    38,
    39,
    40,
    41,
    42,
    43,
    44,
    45,
    46,
    47,
    48,
    49
  ],
  "modelUsed": "gemini-3-flash-preview",
  "interventions": {
    "studyInterventions": [
      {
        "id": "int_1",
        "name": "Canagliflozin",
        "type": {
          "id": "e76db6f3-9bf0-4751-8e34-64e06fb61138",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "role": {
          "id": "b38090d3-5802-4c2d-a5bf-7bd603fd8cbd",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Sodium-glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus and diabetic nephropathy.",
        "productIds": [
          "prod_1"
        ],
        "administrationIds": [
          "admin_1"
        ]
      },
      {
        "id": "int_2",
        "name": "Placebo",
        "type": {
          "id": "88e3bae1-3ed2-4bc6-8279-fe8b36822cc7",
          "code": "C41132",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Placebo",
          "instanceType": "Code"
        },
        "role": {
          "id": "48639825-20e2-441a-83a5-cb2a83ce9a73",
          "code": "C41132",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Placebo",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Matching placebo capsules for single-blind run-in and double-blind treatment phases.",
        "productIds": [
          "prod_2"
        ],
        "administrationIds": [
          "admin_2"
        ]
      },
      {
        "id": "int_3",
        "name": "ACEi or ARB",
        "type": {
          "id": "8b3407f8-f5f8-41fe-a799-470f2217ce6d",
          "code": "C54127",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Background Therapy",
          "instanceType": "Code"
        },
        "role": {
          "id": "24f2dcd3-1dd3-4059-a1f5-d8214e4a1627",
          "code": "C54127",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Background Therapy",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Maximum tolerated labeled daily dose of an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker required for at least 4 weeks prior to randomization."
      },
      {
        "id": "int_4",
        "name": "Antihyperglycemic agents (AHA)",
        "type": {
          "id": "b1002285-f51b-4cb0-a585-175f42ec45d8",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "4a53d663-abe9-4ada-aa8c-6c8be8ca71f7",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Background AHA regimen adjusted to achieve glycemic goals using standard local guidelines."
      },
      {
        "id": "int_5",
        "name": "Mineralocorticoid receptor antagonist (MRA)",
        "type": {
          "id": "975efb8c-5c8a-4ca4-8ec5-121894ac5b39",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "7ea38f13-9647-4832-a3e0-e3a4ed44a479",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Restricted post-baseline use permitted if medically necessary; requires frequent monitoring of serum potassium."
      },
      {
        "id": "int_6",
        "name": "Direct renin inhibitor (DRI)",
        "type": {
          "id": "be25d534-196c-478b-9651-91edb7236772",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "c0d1e909-463e-41a1-b9c0-801ca683c3e0",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Subjects must be off therapy for at least 8 weeks prior to randomization."
      },
      {
        "id": "int_7",
        "name": "SGLT2 inhibitors",
        "type": {
          "id": "e7873fb0-420e-42d6-a960-3a356072018e",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "8c2524cb-1df9-4d36-9f72-07d468ac3b15",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Current use of other SGLT2 inhibitors is prohibited."
      }
    ],
    "administrableProducts": [
      {
        "id": "prod_1",
        "name": "Canagliflozin capsules",
        "administrableDoseForm": {
          "id": "3bf70006-1dad-45b2-b9b6-2523ee27d6c1",
          "code": "C25158",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Capsule",
          "standardCode": {
            "id": "e9acf5b5-39d0-4a14-a7f1-fae912d4f463",
            "code": "C25158",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Capsule",
            "instanceType": "Code"
          },
          "instanceType": "Code"
        },
        "productDesignation": {
          "id": "0fa1e3ed-f7ff-4ec6-acdc-a0b3a4dea34d",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "instanceType": "AdministrableProduct",
        "strength": "100 mg",
        "substanceIds": [
          "sub_1"
        ],
        "manufacturer": "Janssen Research & Development"
      },
      {
        "id": "prod_2",
        "name": "Placebo capsules",
        "administrableDoseForm": {
          "id": "cdff1dab-8959-41c9-a8c9-b3805765809e",
          "code": "C25158",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Capsule",
          "standardCode": {
            "id": "38dc72c9-e42b-4d9e-a910-15de85c870f8",
            "code": "C25158",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Capsule",
            "instanceType": "Code"
          },
          "instanceType": "Code"
        },
        "productDesignation": {
          "id": "392833c5-dcfe-482b-b1ff-b08defe8c8cb",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "instanceType": "AdministrableProduct",
        "strength": "0 mg",
        "manufacturer": "Janssen Research & Development"
      }
    ],
    "administrations": [
      {
        "id": "admin_1",
        "name": "Single-blind Run-in",
        "instanceType": "Administration",
        "dose": "1 capsule",
        "doseFrequency": "once daily",
        "route": {
          "code": "Oral",
          "codeSystem": "USDM",
          "decode": "Oral"
        },
        "duration": "2 weeks"
      },
      {
        "id": "admin_2",
        "name": "Double-blind Treatment",
        "instanceType": "Administration",
        "dose": "100 mg",
        "doseFrequency": "once daily",
        "route": {
          "code": "Oral",
          "codeSystem": "USDM",
          "decode": "Oral"
        },
        "duration": "Estimated 5 to 5.5 years (event-driven)"
      }
    ],
    "substances": [
      {
        "id": "sub_1",
        "name": "Canagliflozin",
        "instanceType": "Substance",
        "description": "JNJ-28431754; (1S)-1,5-anhydro-1-[3-[[5-(4-fluorophenyl)-2-thienyl]methyl]-4-methylphenyl]-D-glucitol"
      }
    ],
    "medicalDevices": [],
    "summary": {
      "interventionCount": 7,
      "productCount": 2,
      "deviceCount": 0
    }
  },
  "rawResponse": {
    "interventions": [
      {
        "name": "Canagliflozin",
        "role": "Investigational Product",
        "description": "Sodium-glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus and diabetic nephropathy."
      },
      {
        "name": "Placebo",
        "role": "Placebo",
        "description": "Matching placebo capsules for single-blind run-in and double-blind treatment phases."
      },
      {
        "name": "ACEi or ARB",
        "role": "Background Therapy",
        "description": "Maximum tolerated labeled daily dose of an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker required for at least 4 weeks prior to randomization."
      },
      {
        "name": "Antihyperglycemic agents (AHA)",
        "role": "Concomitant Medication",
        "description": "Background AHA regimen adjusted to achieve glycemic goals using standard local guidelines."
      },
      {
        "name": "Mineralocorticoid receptor antagonist (MRA)",
        "role": "Concomitant Medication",
        "description": "Restricted post-baseline use permitted if medically necessary; requires frequent monitoring of serum potassium."
      },
      {
        "name": "Direct renin inhibitor (DRI)",
        "role": "Concomitant Medication",
        "description": "Subjects must be off therapy for at least 8 weeks prior to randomization."
      },
      {
        "name": "SGLT2 inhibitors",
        "role": "Concomitant Medication",
        "description": "Current use of other SGLT2 inhibitors is prohibited."
      }
    ],
    "products": [
      {
        "name": "Canagliflozin capsules",
        "doseForm": "Capsule",
        "strength": "100 mg",
        "manufacturer": "Janssen Research & Development"
      },
      {
        "name": "Placebo capsules",
        "doseForm": "Capsule",
        "strength": "0 mg",
        "manufacturer": "Janssen Research & Development"
      }
    ],
    "substances": [
      {
        "name": "Canagliflozin",
        "description": "JNJ-28431754; (1S)-1,5-anhydro-1-[3-[[5-(4-fluorophenyl)-2-thienyl]methyl]-4-methylphenyl]-D-glucitol"
      }
    ],
    "administrations": [
      {
        "name": "Single-blind Run-in",
        "dose": "1 capsule",
        "frequency": "once daily",
        "route": "Oral",
        "duration": "2 weeks"
      },
      {
        "name": "Double-blind Treatment",
        "dose": "100 mg",
        "frequency": "once daily",
        "route": "Oral",
        "duration": "Estimated 5 to 5.5 years (event-driven)"
      }
    ],
    "devices": []
  }
}